Drug Patents owned by Collegium Pharm Inc

1. Drug name - NUCYNTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(a month ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

CN1077566C COLLEGIUM PHARM INC Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds
Jul, 2015

(7 years ago)

CN1125221A COLLEGIUM PHARM INC Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds
Jul, 2015

(7 years ago)

CN1997621A COLLEGIUM PHARM INC Crystalline Form Of (-)-(1R, 2R)-3-(3-Dimethylamino-1-Ethide-2-Methyl Propyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

CN1997621B COLLEGIUM PHARM INC (-)-(1R, 2R) -3-(3-Dimethylamino - -1 - Ethyl -2 - Methyl Propyl) - Phenol Hydrochloride Of Crystalline Form
Jun, 2025

(2 years from now)

IN242353B COLLEGIUM PHARM INC Crystalline Forms Of (-) -(1R, 2R) -3-(3-Dime Thylamino-1- Ethyl -2 Methyl Propyl ) -Phenol Hydrochlo Ride
Jun, 2025

(2 years from now)

IN200603453P2 COLLEGIUM PHARM INC Crystalline Forms Of (−)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

EP693475B1 COLLEGIUM PHARM INC 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity
Jul, 2020

(2 years ago)

EP693475A1 COLLEGIUM PHARM INC 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity
Jul, 2020

(2 years ago)

EP1612203B1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2024

(1 year, 8 months from now)

EP1612203A1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2024

(1 year, 8 months from now)

EP1799633A2 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

EP1799633B1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Discontinued

2. Drug name - NUCYNTA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(a month ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

CN1077566C COLLEGIUM PHARM INC Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds
Jul, 2015

(7 years ago)

CN1125221A COLLEGIUM PHARM INC Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds
Jul, 2015

(7 years ago)

CN1997621A COLLEGIUM PHARM INC Crystalline Form Of (-)-(1R, 2R)-3-(3-Dimethylamino-1-Ethide-2-Methyl Propyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

CN1997621B COLLEGIUM PHARM INC (-)-(1R, 2R) -3-(3-Dimethylamino - -1 - Ethyl -2 - Methyl Propyl) - Phenol Hydrochloride Of Crystalline Form
Jun, 2025

(2 years from now)

IN242353B COLLEGIUM PHARM INC Crystalline Forms Of (-) -(1R, 2R) -3-(3-Dime Thylamino-1- Ethyl -2 Methyl Propyl ) -Phenol Hydrochlo Ride
Jun, 2025

(2 years from now)

IN200603453P2 COLLEGIUM PHARM INC Crystalline Forms Of (−)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

EP693475B1 COLLEGIUM PHARM INC 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity
Jul, 2020

(2 years ago)

EP693475A1 COLLEGIUM PHARM INC 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity
Jul, 2020

(2 years ago)

EP1612203B1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2024

(1 year, 8 months from now)

EP1612203A1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2024

(1 year, 8 months from now)

EP1799633A2 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

EP1799633B1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007156 COLLEGIUM PHARM INC Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol Oct, 2022

(18 days from now)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form Oct, 2024

(2 years from now)

US8536130 COLLEGIUM PHARM INC Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain Sep, 2028

(5 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: Relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy; Management of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 250MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

3. Drug name - XTAMPZA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525053 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs Jul, 2023

(9 months from now)

US9248195 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs Jul, 2023

(9 months from now)

US8840928 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs Jul, 2023

(9 months from now)

US10525052 COLLEGIUM PHARM INC Abuse-deterrent drug formulations Jul, 2023

(9 months from now)

US9044398 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs Jul, 2023

(9 months from now)

US9592200 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs Jul, 2023

(9 months from now)

US9763883 COLLEGIUM PHARM INC Abuse-deterrent drug formulations Jul, 2023

(9 months from now)

US8557291 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs Mar, 2025

(2 years from now)

US7399488 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs Mar, 2025

(2 years from now)

US8449909 COLLEGIUM PHARM INC Abuse-deterrent drug formulations Mar, 2025

(2 years from now)

US7771707 COLLEGIUM PHARM INC Abuse-deterrent drug formulations Mar, 2025

(2 years from now)

US8758813 COLLEGIUM PHARM INC Abuse-deterrent drug formulations Jun, 2025

(2 years from now)

US10668060 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs Dec, 2030

(8 years from now)

US10004729 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs Dec, 2030

(8 years from now)

US9682075 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs Dec, 2030

(8 years from now)

US10646485 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

US9968598 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

US10188644 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

US9737530 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

Drugs and Companies using OXYCODONE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
9MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
13.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
18MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
27MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
36MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.